A Phase 1/2 interventional study of Atezolizumab and Cobimetinib in Carcinoma, Non-Small-Cell Lung, sponsored by Hoffmann-La Roche. Terminated at 29 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (NSCLC).
Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of participants with tumor PD-L1 expression who have received no prior systemic therapy for metastatic NSCLC, and Cohort 2 will consist of participants who experienced disease progression during or following treatment with a platinum-containing regimen and a PD-L1/PD-1 checkpoint inhibitor, given in combination as one line of therapy or as two separate lines of therapy, regardless of PD-L1 expression. In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). Participants who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment regimen (Stage 2).
7,620 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
This study's enrollment of 314 is above the median of 62 across 6,019 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Hoffmann-La Roche is the lead sponsor of 2,101 studies on the registry; 87 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
General Inclusion Criteria
Inclusion Criteria for Cohort 1
Inclusion Criteria for Cohort 2
- Disease progression during or following treatment for metastatic or locally advanced, inoperable NSCLC
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the Atezolizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.
Drug: Atezolizumab
Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria. Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Drug: Atezolizumab · Drug: Cobimetinib
Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria. Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Drug: Atezolizumab · Drug: RO6958688 · Drug: Tocilizumab
Participants in the Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or disease progression. Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Drug: Docetaxel
Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Drug: Atezolizumab · Drug: Cobimetinib
Participants in the Atezolizumab + CPI-444 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Drug: Atezolizumab · Drug: CPI-444
Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Drug: Atezolizumab · Drug: RO6958688 · Drug: Tocilizumab
Participants in the Atezolizumab + Ipatasertib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Drug: Atezolizumab · Drug: Ipatasertib
Participants in Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Drug: Atezolizumab · Drug: Docetaxel
Participants in Atezolizumab + Bevacizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Drug: Atezolizumab · Drug: Bevacizumab
Participants in the Atezolizumab + Pemetrexed + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Drug: Atezolizumab · Drug: Pemetrexed · Drug: Carboplatin
Participants in the Atezolizumab + Gemcitabine + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Drug: Atezolizumab · Drug: Carboplatin · Drug: Gemcitabine
Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Drug: Atezolizumab · Drug: RO6958688 · Drug: Tocilizumab
Participants in the Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit. Participants who have received treatment with Atezolizumab + Docetaxel in Stage 1 will not receive this treatment in Stage 2.
Drug: Atezolizumab · Drug: Docetaxel
Participants in the Atezolizumab + Linagliptin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Drug: Atezolizumab · Drug: Linagliptin
Participants in the Atezolizumab + Sacituzumab Govitecan arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Drug: Atezolizumab · Drug: Sacituzumab Govitecan
Participants in the Atezolizumab + Bevacizumab + Radioatherapy arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Drug: Atezolizumab · Drug: Bevacizumab · Other: Radiation
Participants in the Atezolizumab + Evolocumab arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
Drug: Atezolizumab · Drug: Evolocumab
Participants in the Atezolizumab + Tiragolumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Drug: Atezolizumab · Drug: Tiragolumab
Participants in the Atezolizumab + Tiragolumab + XL092 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Drug: Atezolizumab · Drug: Tiragolumab · Drug: XL092
Participants in the Atezolizumab + Camonsertib arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Drug: Atezolizumab · Drug: Camonsertib
Participants in the Atezolizumab + Bevacizumab + Comonsertib arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Drug: Atezolizumab · Drug: Bevacizumab · Drug: Camonsertib
Participants in the Atezolizumab + Bevacizumab + Tiragolumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Drug: Atezolizumab · Drug: Bevacizumab · Drug: Tiragolumab
Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.
Cobimetinib is administered orally on Days 1-21 of a 28 day cycle.
Cycle 1: RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle at increasing dosage. Subsequent cycles: RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle.
Docetaxel is administered by IV on Day 1 of each 21 day cycle.
CPI-444 is administered orally twice daily on Days 1- 21, of a 21 day cycle.
Pemetrexed is administered by IV on Day 1 of a 21 day cycle.
Carboplatin is administered by IV on day 1 of the first 4 or 6 cycles out of a 21 day cycle.
Gemcitabine is administered by IV on Days 1 and 8 of the first 4 or 6 cycles out of a 21 day cycle.
Linagliptin is administered orally once daily on Days 1 to 21 out of a 21 day cycle.
Tocilizumab is administered for the management of cytokine-release syndrome in the RO6958688-containing arms.
Ipatasertib will be administered orally once a day on Days 1-21 of each 28-day cycle.
Bevacizumab is administered by IV on Day 1 of each 21-day cycle.
Sacituzumab Govitecan is administered by IV on Day 1 and 8 of each 21-day cycle.
Radiotherapy up to 21 days
Evolocumab is administered subcutaneously at a dose of 140 mg on Days 1 and 15 of each 28-day cycle.
Tiragolumab is administered on Day 1 of each 21 day cycle.
XL092 is administered orally once a day on Day 1 to Day 21 of a 21 day cycle.
Also known as: Zanzalintinib
Camonsertib is administered orally on Days 1-3, Days 8-10 of a 21 day cycle.
Stage 1: Percentage of Participants With Objective Response (OR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)
OR was defined as a complete response (CR) or partial response (PR) on two consecutive occasions, ≥4 weeks apart, during Stage 1 as determined by the investigator using RECIST v.1.1. Objective response rate (ORR) was defined as the percentage of participants with OR. CR was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of all target lesions, taking as reference the baseline SOD, in the absence of CR. 95% confidence intervals (CI) for rates were constructed using Clopper-Pearson method. Percentages have been rounded off. The participant in the 'Stage 1 Cohort 2 (S1C2): Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.
Time frame: Up to 50.4 months
Stage 1: Progression-free Survival (PFS) as Determined by Investigator According to RECIST V1.1
PFS was defined as the time from study treatment initiation to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or unequivocal progression of existing non-target lesions. Participants who did not have documented PD or death, PFS was censored at the day of the last tumor assessment. Kaplan-Meier (K-M) method was used to estimate PFS. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.
Time frame: From randomization to the first occurrence of PD or death (Up to 48.6 months)
Stage 1: PFS Rate at Month 6
PFS was defined as the time from study treatment initiation to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or unequivocal progression of existing non-target lesions. Participants who did not have documented PD or death, PFS was censored at the day of the last tumor assessment. The KM approach was used to estimate the percentage of participants who were event-free for PFS at Month 6. Percentages have been rounded off. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.
Time frame: At Month 6
Stage 1: Overall Survival (OS)
OS was defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. K-M method was used to estimate OS. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.
Time frame: From randomization to death (Up to 67 months)
Stage 1: OS Rate at Month 6
OS was defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. The Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for OS at Month 6. Percentages have been rounded off. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.
Time frame: At Month 6
Stage 1: Duration of Response (DOR), as Determined by Investigator According to RECIST V1.1
DOR was defined as the time from the first occurrence of a documented OR until the time of documented PD or death from any cause, whichever occurred first as per investigator assessment using RECIST v1.1. DOR was calculated for participants who had a best confirmed OR of CR/PR. CR and PR were defined as outlined in the description for ORR outcome measure. PD=at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or unequivocal progression of existing non-target lesions. Participants who did not have documented PD or death, DOR was censored at the day of the last tumor assessment. K-M method was used to estimate DOR. The participant in the 'S1C2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.
Time frame: From first occurrence of a documented OR until the time of documented PD or death (Up to 50.4 months)
Stage 1: Percentage of Participants With Disease Control (DC), as Determined by Investigator According to RECIST V1.1
DC was defined as stable disease (SD) for ≥ 12 weeks or a CR or PR, as determined by the investigator according to RECIST v1.1 Disease control rate (DCR) was defined as the percentage of participants with DC. CR was defined as the disappearance of all target \& non-target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD=at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or unequivocal progression of existing non-target lesions. Percentages have been rounded off.
Time frame: Up to 50.4 months
Stages 1 and 2: Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. SAEs = Serious AEs; AESIs = Adverse Events of Special Interest.
Time frame: From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months)
A total of 314 participants with metastatic non-small cell lung cancer (NSCLC) took part in the study from 27 Dec 2017 to 25 Nov 2025. The study had 2 cohorts: Cohort 1: participants with no prior systemic therapy for metastatic NSCLC \& Cohort 2: participants with 1 prior line of systemic therapy for NSCLC. Multiple combination therapies were compared against common control(s) in Cohorts 1 and 2.
| Milestone | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + Cibisatamab (CEA-TCB) | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Idasanutlin + Docetaxel | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + Sacituzumab Govitecan (SG) | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib | Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab | Stage 2 Cohort 2: Docetaxel + Atezolizumab | Stage 2 Cohort 2: Atezolizumab + Linagliptin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 5 | 1 | 1 | 66 | 15 | 1 | 16 | 18 | 31 | 1 | 41 | 45 | 30 | 32 | 8 | 0 | 0 | 0 |
| Safety-evaluable population | 3 | 5 | 1 | 1 | 61 | 15 | 1 | 15 | 16 | 30 | 0 | 40 | 43 | 30 | 31 | 8 | 0 | 0 | 0 |
| Completed | 1 | 5 | 1 | 1 | 52 | 10 | 1 | 12 | 13 | 29 | 0 | 37 | 34 | 28 | 31 | 7 | 0 | 0 | 0 |
| Not completed | 2 | 0 | 0 | 0 | 14 | 5 | 0 | 4 | 5 | 2 | 1 | 4 | 11 | 2 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 | 0 | 4 | 2 | 0 | 3 | 2 | 0 | 0 | 3 | 4 | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 10 | 2 | 0 | 0 | 3 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + Cibisatamab (CEA-TCB) | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Idasanutlin + Docetaxel | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + Sacituzumab Govitecan (SG) | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib | Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab | Stage 2 Cohort 2: Docetaxel + Atezolizumab | Stage 2 Cohort 2: Atezolizumab + Linagliptin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 33 | 22 |
| Safety-evaluable population | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 32 | 20 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 28 | 19 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 3 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 2 |
| Milestone | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + Cibisatamab (CEA-TCB) | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Idasanutlin + Docetaxel | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + Sacituzumab Govitecan (SG) | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib | Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab | Stage 2 Cohort 2: Docetaxel + Atezolizumab | Stage 2 Cohort 2: Atezolizumab + Linagliptin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 4 | 0 | 1 | 36 | 9 | 1 | 9 | 11 | 20 | 0 | 26 | 28 | 20 | 30 | 5 | 2 | 28 | 19 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 4 | 0 | 1 | 36 | 9 | 1 | 9 | 11 | 20 | 0 | 26 | 28 | 20 | 30 | 5 | 2 | 28 | 19 |
| Withdrew: Arm terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 5 | 0 | 0 | 3 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 6 | 2 | 0 | 2 | 1 | 3 | 0 | 2 | 2 | 1 | 4 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 0 | 0 | 2 | 1 |
| Withdrew: Death | 1 | 3 | 0 | 1 | 29 | 7 | 1 | 6 | 8 | 14 | 0 | 19 | 17 | 18 | 25 | 2 | 0 | 24 | 17 |
OR was defined as a complete response (CR) or partial response (PR) on two consecutive occasions, ≥4 weeks apart, during Stage 1 as determined by the investigator using RECIST v.1.1. Objective response rate (ORR) was defined as the percentage of participants with OR. CR was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of all target lesions, taking as reference the baseline SOD, in the absence of CR. 95% confidence intervals (CI) for rates were constructed using Clopper-Pearson method. Percentages have been rounded off. The participant in the 'Stage 1 Cohort 2 (S1C2): Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.
| percentage of participants | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + CEA-TCB | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + SG | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1: Percentage of Participants With Objective Response (OR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1) | 33.3 (0.84 to 90.57) | 0 (0.00 to 52.18) | 100 (2.50 to 100.00) | 0 (0.00 to 97.50) | 13.1 (5.84 to 24.22) | 0 (0.00 to 21.80) | 0 (0.00 to 97.50) | 6.7 (0.17 to 31.95) | 6.3 (0.16 to 30.23) | 6.7 (0.82 to 22.07) | 20.0 (9.05 to 35.65) | 16.7 (6.37 to 32.81) | 6.7 (0.82 to 22.07) | 3.2 (0.08 to 16.70) | 0 (0.00 to 36.94) |
PFS was defined as the time from study treatment initiation to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or unequivocal progression of existing non-target lesions. Participants who did not have documented PD or death, PFS was censored at the day of the last tumor assessment. Kaplan-Meier (K-M) method was used to estimate PFS. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.
| months | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + CEA-TCB | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + SG | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1: Progression-free Survival (PFS) as Determined by Investigator According to RECIST V1.1 | 1.51 (1.31 to NA) | 2.66 (0.69 to NA) | 6.90 (NA to NA) | 1.64 (NA to NA) | 4.83 (4.11 to 5.91) | 2.43 (1.84 to 6.77) | 17.48 (NA to NA) | 2.30 (1.38 to 5.52) | 5.09 (3.22 to 8.54) | 2.64 (1.71 to 3.98) | 6.95 (4.37 to 8.28) | 7.93 (4.67 to 15.67) | 5.49 (4.27 to 7.16) | 2.17 (1.48 to 4.37) | 3.50 (1.54 to 5.75) |
PFS was defined as the time from study treatment initiation to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or unequivocal progression of existing non-target lesions. Participants who did not have documented PD or death, PFS was censored at the day of the last tumor assessment. The KM approach was used to estimate the percentage of participants who were event-free for PFS at Month 6. Percentages have been rounded off. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.
| percentage of participants | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + CEA-TCB | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + SG | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1: PFS Rate at Month 6 | 33.33 (0.00 to 86.68) | 20.00 (0.00 to 55.06) | 100.00 (100.00 to 100.00) | NA (NA to NA) | 36.79 (23.61 to 49.96) | 29.22 (3.33 to 55.11) | 100.00 (100.00 to 100.00) | 26.67 (4.29 to 49.05) | 37.50 (13.78 to 61.22) | 20.00 (5.69 to 34.31) | 55.00 (39.58 to 70.42) | 61.11 (45.19 to 77.04) | 43.33 (25.60 to 61.07) | 12.90 (1.10 to 24.70) | 12.50 (0.00 to 35.42) |
OS was defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. K-M method was used to estimate OS. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.
| months | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + CEA-TCB | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + SG | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1: Overall Survival (OS) | 2.96 (2.30 to NA) | 32.66 (10.94 to NA) | NA (NA to NA) | 3.48 (NA to NA) | 9.63 (8.34 to 14.78) | 7.75 (1.91 to 16.56) | 17.48 (NA to NA) | 11.53 (2.07 to 17.22) | 9.40 (4.63 to 23.59) | 12.45 (5.59 to 15.51) | 13.70 (10.61 to 21.06) | 16.92 (9.76 to 33.71) | 12.48 (7.62 to 17.64) | 9.10 (7.82 to 14.55) | NA (6.21 to NA) |
OS was defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. The Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for OS at Month 6. Percentages have been rounded off. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.
| percentage of participants | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + CEA-TCB | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + SG | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1: OS Rate at Month 6 | 33.33 (0.00 to 86.68) | 100.00 (100.00 to 100.00) | 100.00 (100.00 to 100.00) | NA (NA to NA) | 78.34 (67.47 to 89.20) | 53.85 (26.02 to 81.67) | 100.00 (100.00 to 100.00) | 60.00 (35.21 to 84.79) | 68.18 (45.06 to 91.30) | 66.92 (49.21 to 84.64) | 82.50 (70.72 to 94.28) | 81.82 (68.66 to 94.98) | 79.62 (65.04 to 94.19) | 75.62 (59.87 to 91.37) | 87.50 (64.58 to 100.00) |
DOR was defined as the time from the first occurrence of a documented OR until the time of documented PD or death from any cause, whichever occurred first as per investigator assessment using RECIST v1.1. DOR was calculated for participants who had a best confirmed OR of CR/PR. CR and PR were defined as outlined in the description for ORR outcome measure. PD=at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or unequivocal progression of existing non-target lesions. Participants who did not have documented PD or death, DOR was censored at the day of the last tumor assessment. K-M method was used to estimate DOR. The participant in the 'S1C2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.
| months | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + CEA-TCB | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + SG | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1: Duration of Response (DOR), as Determined by Investigator According to RECIST V1.1 | 30.39 (NA to NA) | — | 5.36 (NA to NA) | — | 7.03 (3.48 to NA) | — | — | 19.09 (NA to NA) | 16.20 (NA to NA) | 4.17 (1.41 to NA) | 14.54 (5.13 to 16.62) | 20.99 (11.10 to NA) | 5.36 (4.17 to NA) | 23.26 (NA to NA) | — |
DC was defined as stable disease (SD) for ≥ 12 weeks or a CR or PR, as determined by the investigator according to RECIST v1.1 Disease control rate (DCR) was defined as the percentage of participants with DC. CR was defined as the disappearance of all target \& non-target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD=at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or unequivocal progression of existing non-target lesions. Percentages have been rounded off.
| percentage of participants | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + CEA-TCB | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + SG | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1: Percentage of Participants With Disease Control (DC), as Determined by Investigator According to RECIST V1.1 | 33.3 (0.84 to 90.57) | 40.0 (5.27 to 85.34) | 100 (2.50 to 100.00) | 0 (0.00 to 97.50) | 57.4 (44.06 to 69.96) | 33.3 (11.82 to 61.62) | 100 (2.50 to 100.00) | 40.0 (16.34 to 67.71) | 56.3 (29.88 to 80.25) | 36.7 (19.93 to 56.14) | 65.0 (48.32 to 79.37) | 69.4 (51.89 to 83.65) | 66.7 (47.19 to 82.71) | 41.9 (24.55 to 60.92) | 37.5 (8.52 to 75.51) |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. SAEs = Serious AEs; AESIs = Adverse Events of Special Interest.
| Participants | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + CEA-TCB | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + SG | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib | Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab | Stage 2 Cohort 2: Docetaxel + Atezolizumab | Stage 2 Cohort 2: Atezolizumab + Linagliptin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stages 1 and 2: Number of Participants With Adverse Events (AEs) | 3 | 5 | 1 | 1 | 60 | 15 | 1 | 15 | 16 | 30 | 38 | 42 | 30 | 30 | 8 | 2 | 31 | 19 |
Collected over From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1 Cohort 1: Control (Atezolizumab) | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Stage 1 Cohort 1: Atezolizumab + Cobimetinib | 3/5 (60%) | 4/5 (80%) | 5/5 (100%) |
| Stage 1 Cohort 1: Atezolizumab + CEA-TCB | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Stage 1 Cohort 1: Atezolizumab + Tiragolumab | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Stage 1 Cohort 2: Control (Docetaxel) | 36/66 (54.5%) | 20/61 (32.8%) | 58/61 (95.1%) |
| Stage 1 Cohort 2: Atezolizumab + Cobimetinib | 10/15 (66.7%) | 8/15 (53.3%) | 13/15 (86.7%) |
| Stage 1 Cohort 2: Atezolizumab + CEA-TCB | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Stage 1 Cohort 2: Atezolizumab + CPI-444 | 10/16 (62.5%) | 8/15 (53.3%) | 14/15 (93.3%) |
| Stage 1 Cohort 2: Docetaxel + Atezolizumab | 10/18 (55.6%) | 5/16 (31.3%) | 16/16 (100%) |
| Stage 1 Cohort 2: Atezolizumab + Ipatasertib | 14/31 (45.2%) | 13/30 (43.3%) | 30/30 (100%) |
| Stage 1 Cohort 2: Atezolizumab + Bevacizumab | 22/41 (53.7%) | 13/40 (32.5%) | 36/40 (90%) |
| Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | 23/45 (51.1%) | 17/43 (39.5%) | 41/43 (95.3%) |
| Stage 1 Cohort 2: Atezolizumab + SG | 19/30 (63.3%) | 14/30 (46.7%) | 30/30 (100%) |
| Stage 1 Cohort 2: Atezolizumab + Evolocumab | 25/32 (78.1%) | 10/31 (32.3%) | 29/31 (93.5%) |
| Stage 1 Cohort 2: Atezolizumab + Camonsertib | 4/8 (50%) | 4/8 (50%) | 8/8 (100%) |
| Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Stage 2 Cohort 2: Docetaxel + Atezolizumab | 29/33 (87.9%) | 13/32 (40.6%) | 30/32 (93.8%) |
| Stage 2 Cohort 2: Atezolizumab + Linagliptin | 19/22 (86.4%) | 6/20 (30%) | 18/20 (90%) |
| Event | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + CEA-TCB | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + SG | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib | Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab | Stage 2 Cohort 2: Docetaxel + Atezolizumab | Stage 2 Cohort 2: Atezolizumab + Linagliptin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/3 | 0/5 | 0/1 | 0/1 | 0/61 | 0/15 | 1/1 | 0/15 | 0/16 | 1/30 | 1/40 | 0/43 | 1/30 | 0/31 | 0/8 | 0/2 | 1/32 | 0/20 |
| ColitisGastrointestinal disorders | 0/3 | 0/5 | 1/1 | 0/1 | 0/61 | 0/15 | 0/1 | 0/15 | 0/16 | 1/30 | 0/40 | 0/43 | 1/30 | 0/31 | 0/8 | 0/2 | 0/32 | 0/20 |
| COVID-19Infections and infestations | 0/3 | 0/5 | 0/1 | 1/1 | 0/61 | 0/15 | 0/1 | 0/15 | 0/16 | 1/30 | 1/40 | 1/43 | 1/30 | 2/31 | 1/8 | 0/2 | 0/32 | 1/20 |
| Respiratory tract infectionInfections and infestations | 0/3 | 0/5 | 0/1 | 1/1 | 0/61 | 0/15 | 0/1 | 0/15 | 0/16 | 1/30 | 1/40 | 1/43 | 1/30 | 0/31 | 0/8 | 0/2 | 1/32 | 0/20 |
| Spinal fractureInjury, poisoning and procedural complications | 0/3 | 1/5 | 0/1 | 0/1 | 0/61 | 0/15 | 1/1 | 0/15 | 0/16 | 0/30 | 0/40 | 0/43 | 0/30 | 0/31 | 0/8 | 0/2 | 0/32 | 0/20 |
| Transaminases increasedInvestigations | 0/3 | 0/5 | 0/1 | 0/1 | 0/61 | 0/15 | 1/1 | 0/15 | 0/16 | 0/30 | 0/40 | 0/43 | 0/30 | 0/31 | 0/8 | 0/2 | 0/32 | 0/20 |
| InfluenzaInfections and infestations | 0/3 | 0/5 | 0/1 | 0/1 | 0/61 | 0/15 | 0/1 | 0/15 | 0/16 | 0/30 | 0/40 | 0/43 | 0/30 | 0/31 | 0/8 | 1/2 | 0/32 | 0/20 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 0/5 | 0/1 | 0/1 | 0/61 | 0/15 | 0/1 | 0/15 | 1/16 | 0/30 | 0/40 | 0/43 | 0/30 | 0/31 | 0/8 | 0/2 | 0/32 | 0/20 |
| Gastric perforationGastrointestinal disorders | 1/3 | 0/5 | 0/1 | 0/1 | 0/61 | 0/15 | 0/1 | 0/15 | 0/16 | 0/30 | 0/40 | 0/43 | 0/30 | 0/31 | 0/8 | 0/2 | 0/32 | 0/20 |
| AstheniaGeneral disorders | 1/3 | 0/5 | 0/1 | 0/1 | 1/61 | 0/15 | 0/1 | 1/15 | 0/16 | 1/30 | 1/40 | 0/43 | 0/30 | 0/31 | 1/8 | 0/2 | 1/32 | 0/20 |
| Event | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + CEA-TCB | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + SG | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib | Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab | Stage 2 Cohort 2: Docetaxel + Atezolizumab | Stage 2 Cohort 2: Atezolizumab + Linagliptin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/3 | 0/5 | 0/1 | 0/1 | 21/61 | 4/15 | 0/1 | 5/15 | 5/16 | 7/30 | 2/40 | 5/43 | 14/30 | 6/31 | 7/8 | 2/2 | 10/32 | 3/20 |
| ConstipationGastrointestinal disorders | 1/3 | 2/5 | 0/1 | 0/1 | 2/61 | 1/15 | 1/1 | 3/15 | 1/16 | 4/30 | 6/40 | 6/43 | 11/30 | 6/31 | 2/8 | 2/2 | 1/32 | 4/20 |
| Dry mouthGastrointestinal disorders | 0/3 | 0/5 | 0/1 | 1/1 | 1/61 | 1/15 | 0/1 | 0/15 | 1/16 | 0/30 | 0/40 | 1/43 | 0/30 | 0/31 | 0/8 | 0/2 | 0/32 | 2/20 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/3 | 0/5 | 1/1 | 0/1 | 3/61 | 0/15 | 0/1 | 0/15 | 0/16 | 1/30 | 1/40 | 2/43 | 1/30 | 0/31 | 1/8 | 0/2 | 0/32 | 0/20 |
| NauseaGastrointestinal disorders | 1/3 | 0/5 | 0/1 | 0/1 | 12/61 | 4/15 | 1/1 | 2/15 | 4/16 | 10/30 | 3/40 | 4/43 | 12/30 | 1/31 | 4/8 | 0/2 | 2/32 | 3/20 |
| AstheniaGeneral disorders | 0/3 | 1/5 | 0/1 | 1/1 | 24/61 | 0/15 | 0/1 | 3/15 | 5/16 | 11/30 | 5/40 | 17/43 | 8/30 | 4/31 | 2/8 | 0/2 | 14/32 | 1/20 |
| FatigueGeneral disorders | 2/3 | 1/5 | 1/1 | 0/1 | 11/61 | 2/15 | 1/1 | 1/15 | 4/16 | 2/30 | 7/40 | 5/43 | 7/30 | 4/31 | 2/8 | 1/2 | 2/32 | 2/20 |
| Biliary obstructionHepatobiliary disorders | 0/3 | 0/5 | 0/1 | 0/1 | 0/61 | 0/15 | 1/1 | 0/15 | 0/16 | 0/30 | 0/40 | 0/43 | 1/30 | 0/31 | 0/8 | 0/2 | 0/32 | 0/20 |
| Seasonal allergyImmune system disorders | 0/3 | 0/5 | 1/1 | 0/1 | 0/61 | 0/15 | 0/1 | 0/15 | 0/16 | 0/30 | 0/40 | 0/43 | 0/30 | 0/31 | 0/8 | 0/2 | 0/32 | 0/20 |
| Escherichia infectionInfections and infestations | 0/3 | 0/5 | 0/1 | 0/1 | 0/61 | 0/15 | 1/1 | 0/15 | 0/16 | 0/30 | 0/40 | 0/43 | 0/30 | 0/31 | 0/8 | 0/2 | 0/32 | 0/20 |
Randomized population included all participants randomized to each treatment arm.
| Age, Categorical(Participants) | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + CEA-TCB | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Idasanutlin + Docetaxel | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + SG | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib | Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab | Stage 2 Cohort 2: Docetaxel + Atezolizumab | Stage 2 Cohort 2: Atezolizumab + Linagliptin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1 — <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0 |
| Stage 1 — Between 18 and 65 years | 0 | 2 | 0 | 0 | 35 | 13 | 0 | 11 | 8 | 16 | 1 | 23 | 17 | 13 | 9 | 6 | — | — | — | 154 |
| Stage 1 — >=65 years | 3 | 3 | 1 | 1 | 31 | 2 | 1 | 5 | 10 | 15 | 0 | 18 | 28 | 17 | 23 | 2 | — | — | — | 160 |
| Stage 2 — <=18 years | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 |
| Stage 2 — Between 18 and 65 years | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 20 | 12 | 32 |
| Stage 2 — >=65 years | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2 | 13 | 10 | 25 |
| Sex: Female, Male(Participants) | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + CEA-TCB | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Idasanutlin + Docetaxel | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + SG | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib | Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab | Stage 2 Cohort 2: Docetaxel + Atezolizumab | Stage 2 Cohort 2: Atezolizumab + Linagliptin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1 — Female | 1 | 1 | 0 | 0 | 18 | 5 | 0 | 7 | 6 | 8 | 1 | 10 | 11 | 8 | 9 | 1 | — | — | — | 86 |
| Stage 1 — Male | 2 | 4 | 1 | 1 | 48 | 10 | 1 | 9 | 12 | 23 | 0 | 31 | 34 | 22 | 23 | 7 | — | — | — | 228 |
| Stage 2 — Female | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 9 | 6 | 15 |
| Stage 2 — Male | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2 | 24 | 16 | 42 |
| Ethnicity (NIH/OMB)(Participants) | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + CEA-TCB | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Idasanutlin + Docetaxel | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + SG | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib | Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab | Stage 2 Cohort 2: Docetaxel + Atezolizumab | Stage 2 Cohort 2: Atezolizumab + Linagliptin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1 — Hispanic or Latino | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | — | — | — | 5 |
| Stage 1 — Not Hispanic or Latino | 3 | 5 | 1 | 1 | 50 | 14 | 1 | 15 | 13 | 19 | 1 | 27 | 31 | 21 | 20 | 6 | — | — | — | 228 |
| Stage 1 — Unknown or Not Reported | 0 | 0 | 0 | 0 | 14 | 1 | 0 | 1 | 5 | 12 | 0 | 13 | 14 | 7 | 12 | 2 | — | — | — | 81 |
| Stage 2 — Hispanic or Latino | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 1 | 2 | 3 |
| Stage 2 — Not Hispanic or Latino | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2 | 22 | 16 | 40 |
| Stage 2 — Unknown or Not Reported | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 10 | 4 | 14 |
| Race (NIH/OMB)(Participants) | Stage 1 Cohort 1: Control (Atezolizumab) | Stage 1 Cohort 1: Atezolizumab + Cobimetinib | Stage 1 Cohort 1: Atezolizumab + CEA-TCB | Stage 1 Cohort 1: Atezolizumab + Tiragolumab | Stage 1 Cohort 2: Control (Docetaxel) | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + CEA-TCB | Stage 1 Cohort 2: Atezolizumab + CPI-444 | Stage 1 Cohort 2: Docetaxel + Atezolizumab | Stage 1 Cohort 2: Atezolizumab + Ipatasertib | Stage 1 Cohort 2: Idasanutlin + Docetaxel | Stage 1 Cohort 2: Atezolizumab + Bevacizumab | Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy | Stage 1 Cohort 2: Atezolizumab + SG | Stage 1 Cohort 2: Atezolizumab + Evolocumab | Stage 1 Cohort 2: Atezolizumab + Camonsertib | Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab | Stage 2 Cohort 2: Docetaxel + Atezolizumab | Stage 2 Cohort 2: Atezolizumab + Linagliptin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1 — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | 1 |
| Stage 1 — Asian | 1 | 3 | 1 | 0 | 15 | 8 | 0 | 4 | 2 | 7 | 0 | 5 | 14 | 5 | 9 | 3 | — | — | — | 77 |
| Stage 1 — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0 |
| Stage 1 — Black or African American | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | 2 |
| Stage 1 — White | 2 | 2 | 0 | 1 | 38 | 5 | 1 | 9 | 11 | 14 | 1 | 27 | 18 | 19 | 11 | 3 | — | — | — | 162 |
| Stage 1 — More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0 |
| Stage 1 — Unknown or Not Reported | 0 | 0 | 0 | 0 | 13 | 1 | 0 | 1 | 5 | 10 | 0 | 9 | 13 | 6 | 12 | 2 | — | — | — | 72 |
| Stage 2 — American Indian or Alaska Native | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 |
| Stage 2 — Asian | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 0 | 1 | 2 |
| Stage 2 — Native Hawaiian or Other Pacific Islander | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 |
| Stage 2 — Black or African American | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 1 | 0 | 1 |
| Stage 2 — White | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 24 | 18 | 43 |
| Stage 2 — More than one race | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 |
| Stage 2 — Unknown or Not Reported | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 8 | 3 | 11 |
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cobimetinib · Cibisatamab · Docetaxel · Ciforadenant · Pemetrexed · Carboplatin · Gemcitabine · Linagliptin · Ipatasertib · Bevacizumab · Sacituzumab govitecan · Evolocumab · Tiragolumab · Zanzalintinib · Camonsertib
Carcinoma, Non-Small-Cell Lung →